Analytical Data
-
Gene name
ITGb6
- Application
-
Alternative Names
ITG-B6
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Z0T9
-
Expression Region
Tyr131~Thr619
-
Molecular Weight
57kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ITGb6, or integrin beta-6, is a member of the integrin family of cell adhesion molecules, playing a crucial role in various biological processes, including cell-matrix adhesion, migration, and signaling. It is primarily expressed in epithelial cells and is implicated in crucial physiological functions, such as wound healing and tissue repair. In recent years, research has highlighted the significance of ITGb6 in various pathological conditions, particularly in cancer, where its overexpression is linked to enhanced tumor growth, metastasis, and poor prognosis. The investigation of ITGb6 as a target for therapeutic intervention has gained momentum, with scientists looking to understand its mechanism of action at the molecular level. Recombining ITGb6 protein has emerged as a key strategy for studying its structure and function, facilitating the exploration of its potential as a biomarker for cancer diagnosis and prognosis. Additionally, engineered ITGb6 proteins can be employed in drug delivery systems and tissue engineering applications, which may ultimately lead to novel therapeutic strategies for cancer and other diseases. This ongoing research is crucial for establishing ITGb6 not only as a therapeutic target but also as a critical player in the understanding of integrin-mediated cellular processes. As the knowledge surrounding ITGb6 expands, so too does the potential for innovative treatments aimed at diseases characterized by dysregulated cell adhesion and migration, highlighting the importance of recombinant ITGb6 protein studies in advancing biomedical research.
